Japan approves iron deficiency drug from Pharmacosmos
With the approval from the Japanese health authorities, Danish pharmaceutical firm Pharmacosmos can now initiate the launch of its iron deficiency anemia treatment in Japan.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Five years after Danish Pharmacosmos entered a strategic collaboration with Japanese partner Nippon Shinyaku on the launch of Monover (ferric derisomaltose) in Japan, the two parties can now initiate the marketing efforts in the country.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pharmacosmos settles legal dispute with Vifor
For subscribers
